Literature DB >> 22205140

Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy.

Vincent Koppelmans1, Michiel B de Ruiter, Fedde van der Lijn, Willem Boogerd, Caroline Seynaeve, Aad van der Lugt, Henri Vrooman, Wiro J Niessen, Monique M B Breteler, Sanne B Schagen.   

Abstract

A limited number of studies have associated adjuvant chemotherapy with structural brain changes. These studies had small sample sizes and were conducted shortly after cessation of chemotherapy. Results of these studies indicate local gray matter volume decrease and an increase in white matter lesions. Up till now, it is unclear if non-CNS chemotherapy is associated with long-term structural brain changes. We compared focal and total brain volume (TBV) of a large set of non-CNS directed chemotherapy-exposed breast cancer survivors, on average 21 years post-treatment, to that of a population-based sample of women without a history of cancer. Structural MRI (1.5T) was performed in 184 chemotherapy-exposed breast cancer patients, mean age 64.0 (SD = 6.5) years, who had been diagnosed with cancer on average 21.1 (SD = 4.4) years before, and 368 age-matched cancer-free reference subjects from a population-based cohort study. Outcome measures were: TBV and total gray and white matter volume, and hippocampal volume. In addition, voxel based morphometry was performed to analyze differences in focal gray matter. The chemotherapy-exposed breast cancer survivors had significantly smaller TBV (-3.5 ml, P = 0.019) and gray matter volume (-2.9 ml, P = 0.003) than the reference subjects. No significant differences were observed in white matter volume, hippocampal volume, or local gray matter volume. This study shows that adjuvant chemotherapy for breast cancer is associated with long-term reductions in TBV and overall gray matter volume in the absence of focal reductions. The observed smaller gray matter volume in chemotherapy-exposed survivors was comparable to the effect of almost 4 years of age on gray matter volume reduction. These volume differences might be associated with the slightly worse cognitive performance that we observed previously in this group of breast cancer survivors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22205140     DOI: 10.1007/s10549-011-1888-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  66 in total

1.  Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study.

Authors:  Brenna C McDonald; Susan K Conroy; Dori J Smith; John D West; Andrew J Saykin
Journal:  Brain Behav Immun       Date:  2012-05-18       Impact factor: 7.217

Review 2.  Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors.

Authors:  M Lange; F Joly; J Vardy; T Ahles; M Dubois; L Tron; G Winocur; M B De Ruiter; H Castel
Journal:  Ann Oncol       Date:  2019-12-01       Impact factor: 32.976

3.  Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer.

Authors:  Shelli R Kesler; Christa L Watson; Douglas W Blayney
Journal:  Neurobiol Aging       Date:  2015-05-01       Impact factor: 4.673

Review 4.  Cognitive Effects of Chemotherapy and Cancer-Related Treatments in Older Adults.

Authors:  Jennifer N Vega; Julie Dumas; Paul A Newhouse
Journal:  Am J Geriatr Psychiatry       Date:  2017-04-06       Impact factor: 4.105

5.  Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage.

Authors:  Susan K Conroy; Brenna C McDonald; Dori J Smith; Lyndsi R Moser; John D West; Lisa M Kamendulis; James E Klaunig; Victoria L Champion; Frederick W Unverzagt; Andrew J Saykin
Journal:  Breast Cancer Res Treat       Date:  2012-12-22       Impact factor: 4.872

Review 6.  Clearing the air: a review of our current understanding of "chemo fog".

Authors:  Erin O'Farrell; Joyce MacKenzie; Barbara Collins
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

7.  Neuroimaging biomarkers and cognitive function in non-CNS cancer and its treatment: current status and recommendations for future research.

Authors:  Andrew J Saykin; Michiel B de Ruiter; Brenna C McDonald; Sabine Deprez; Daniel H S Silverman
Journal:  Brain Imaging Behav       Date:  2013-12       Impact factor: 3.978

8.  A prospective evaluation of changes in brain structure and cognitive functions in adult stem cell transplant recipients.

Authors:  D D Correa; J C Root; R Baser; D Moore; K K Peck; E Lis; T B Shore; H T Thaler; A Jakubowski; N Relkin
Journal:  Brain Imaging Behav       Date:  2013-12       Impact factor: 3.978

Review 9.  Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.

Authors:  Jeffrey S Wefel; Shelli R Kesler; Kyle R Noll; Sanne B Schagen
Journal:  CA Cancer J Clin       Date:  2014-12-05       Impact factor: 508.702

10.  Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy.

Authors:  Shelli R Kesler; Christa Watson; Della Koovakkattu; Clement Lee; Ruth O'Hara; Misty L Mahaffey; Jeffrey S Wefel
Journal:  Brain Imaging Behav       Date:  2013-12       Impact factor: 3.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.